Is there another way to take account of noncompliance in randomized controlled trials?

Hewitt, Catherine E.; Torgerson, David J.; Miles, Jeremy N. V.
August 2005
CMAJ: Canadian Medical Association Journal;8/15/2006, Vol. 175 Issue 4, p347
Academic Journal
This article focuses on alternative ways of taking account of noncompliance in the design and conduct of randomized controlled trials (RCT). It has been recommended that the primary analysis of an RCT should utilize intention to treat (ITT). An alternative to the ITT approach is the complier average causal effect, which is also known as the local average treatment effect. A chart is presented which compared rate of death from colorectal cancer among those who attended or did not attend medical screening.


Related Articles

  • Any casualties in the clash of randomised and observational evidence? Ioannidis, John P A; Haidich, Anna-Bettina; Lau, Joseph // BMJ: British Medical Journal (International Edition);04/14/2001, Vol. 322 Issue 7291, p879 

    Editorial. Discusses the use of randomized controlled trials and observational studies in clinical research. Concordance between estimates obtained with the two research designs; Option of viability; Limitations of the studies.

  • Breast cancer screening programme as setting for an adjunct research project: effect on programme attendance. Gram, Inger T.; Lund, Eiliv // Journal of Medical Screening;Mar2008, Vol. 15 Issue 1, p44 

    The purpose of this randomized controlled trial was to examine if an adjunct research project to a breast cancer screening programme would affect the high programme attendance. Women residing in the municipality of Tromsø aged 55 years or older, scheduled to receive an invitation letter to...

  • Does Published Evidence Reflect the Whole Story?  // Clinical Oncology Alert;Apr2008 Primary Care, Vol. 13 Issue 4, p7 

    The article discusses a research on the effect of non-publication of clinical trials on drug testing results. It references a study by E. H. Turner et al, published in a 2008 issue of the "New England Journal of Medicine." The research found that 11 of the 22 negative trials were published in an...

  • In Vivo Parasitological Measures of Artemisinin Susceptibility. Stepniewska, Kasia; Ashley, Elizabeth; Lee, Sue J.; Anstey, Nicholas; Barnes, Karen I.; Tran Quang Binh; D'Alessandro, Umberto; Day, Nicholas P. J.; de Vries, Peter J.; Dorsey, Grant; Guthmann, Jean-Paul; Mayxay, Mayfong; Newton, Paul N.; Olliaro, Piero; Osorio, Lyda; Price, Ric N.; Rowland, Mark; Smithuis, Frank; Taylor, Walter R. J.; Nosten, François // Journal of Infectious Diseases;2/15/2010, Vol. 201 Issue 4, p570 

    Parasite clearance data from 18,699 patients with falciparum malaria treated with an artemisinin derivative in areas of low (n=14,539), moderate (n=2077), and high (n=2083) levels of malaria transmission across the world were analyzed to determine the factors that affect clearance rates and...

  • Design of Cancer Screening Trials/Randomized Trials for Evaluation of Cancer Screening. Miller, Anthony B. // World Journal of Surgery;Jul2006, Vol. 30 Issue 7, p1152 

    The article reports on the use of randomized screening trials(RST) in evaluating the effectiveness of screening for cancer. Several aspects of RST's design which were in used is discussed such as the appropriate time to conduct RST, study population selection, randomization and administration of...

  • Planning of randomized early detection trials. Ping Hu; Zelen, Marvin // Statistical Methods in Medical Research;Dec2004, Vol. 13 Issue 6, p491 

    Consider a randomized clinical trial to evaluate the benefit of screening an asymptomatic population. Suppose that the subjects are randomized into a usual care and a study group. The study group receives one or more periodic early detection examinations aimed at diagnosing disease early, when...

  • What is the role of iFOBT in screening for colorectal cancer? Ransohoff, David F. // Gut;Oct2007, Vol. 56 Issue 10, p1343 

    The article discusses the Policy makers will need to consider if it has one, not only as an adjunct to Guaiac Fecal-Occult Blood Test (gFOBT) screening. As a primary screening test s creening for colorectal cancer using gFOBT has been shown in randomized controlled trials to reduce colorectal...

  • Registering CIHR-funded randomized controlled trials:a global public good. Moher, David; Bernstein, Alan // CMAJ: Canadian Medical Association Journal;9/28/2004, Vol. 171 Issue 7, p750 

    Commends the decision of the Canadian Institutes of Health Research to adopt a registry for all randomized controlled trials it funded. Information on the International Standard Randomized Controlled Trial Number; Significance of trial registry; Company which developed the agency's trial registry.

  • Europe's Personalized Future. O'Donnell, Peter // Applied Clinical Trials;Sep2007, Vol. 16 Issue 9, p30 

    The article reports that the German government has released a paper which predicts a bold future for biomedicine in Europe in the next 20 years. The said document emphasizes the changes in the nature of clinical trials based on personalized medicine. The paper also stresses the importance of...


Read the Article


Sign out of this library

Other Topics